These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 34381451)

  • 1. Individual
    Schetelig J; Heidenreich F; Baldauf H; Trost S; Falk B; Hoßbach C; Real R; Roers A; Lindemann D; Dalpke A; Kolditz M; de With K; Bornhäuser M; Bonifacio EE; Rücker-Braun E; Lange V; Markert J; Barth R; Hofmann JA; Sauter J; Bernas SN; Schmidt AH
    Front Immunol; 2021; 12():698193. PubMed ID: 34381451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
    Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
    Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2.
    Nguyen A; David JK; Maden SK; Wood MA; Weeder BR; Nellore A; Thompson RF
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32303592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concern.
    López D
    Front Immunol; 2022; 13():832889. PubMed ID: 35154154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein.
    Rakib A; Sami SA; Mimi NJ; Chowdhury MM; Eva TA; Nainu F; Paul A; Shahriar A; Tareq AM; Emon NU; Chakraborty S; Shil S; Mily SJ; Ben Hadda T; Almalki FA; Emran TB
    Comput Biol Med; 2020 Sep; 124():103967. PubMed ID: 32828069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2.
    Kiyotani K; Toyoshima Y; Nemoto K; Nakamura Y
    J Hum Genet; 2020 Jul; 65(7):569-575. PubMed ID: 32372051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
    Cun Y; Li C; Shi L; Sun M; Dai S; Sun L; Shi L; Yao Y
    Hum Vaccin Immunother; 2021 Apr; 17(4):1097-1108. PubMed ID: 33175614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoinformatic approach to assess SARS-CoV-2 protein S epitopes recognised by the most frequent MHC-I alleles in the Brazilian population.
    Moura RR; Agrelli A; Santos-Silva CA; Silva N; Assunção BR; Brandão L; Benko-Iseppon AM; Crovella S
    J Clin Pathol; 2021 Aug; 74(8):528-532. PubMed ID: 32759312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients.
    Iturrieta-Zuazo I; Rita CG; García-Soidán A; de Malet Pintos-Fonseca A; Alonso-Alarcón N; Pariente-Rodríguez R; Tejeda-Velarde A; Serrano-Villar S; Castañer-Alabau JL; Nieto-Gañán I
    Clin Immunol; 2020 Oct; 219():108572. PubMed ID: 32810602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
    Tahir Ul Qamar M; Shahid F; Aslam S; Ashfaq UA; Aslam S; Fatima I; Fareed MM; Zohaib A; Chen LL
    Infect Dis Poverty; 2020 Sep; 9(1):132. PubMed ID: 32938504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic, Unbiased Mapping of CD8
    Stryhn A; Kongsgaard M; Rasmussen M; Harndahl MN; Østerbye T; Bassi MR; Thybo S; Gabriel M; Hansen MB; Nielsen M; Christensen JP; Randrup Thomsen A; Buus S
    Front Immunol; 2020; 11():1836. PubMed ID: 32983097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants.
    de Sousa E; Ligeiro D; Lérias JR; Zhang C; Agrati C; Osman M; El-Kafrawy SA; Azhar EI; Ippolito G; Wang FS; Zumla A; Maeurer M
    Int J Infect Dis; 2020 Sep; 98():454-459. PubMed ID: 32693089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-Predicted MHC Class II Epitope Presentation of SARS-CoV-2 Structural Proteins Correlates to the Case Fatality Rates of COVID-19 in Different Countries.
    Liang C; Bencurova E; Psota E; Neurgaonkar P; Prelog M; Scheller C; Dandekar T
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of 174 COVID-19 vaccine candidate epitopes reveals low performance of common epitope prediction tools.
    Prachar M; Justesen S; Steen-Jensen DB; Thorgrimsen S; Jurgons E; Winther O; Bagger FO
    Sci Rep; 2020 Nov; 10(1):20465. PubMed ID: 33235258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2.
    Chen HZ; Tang LL; Yu XL; Zhou J; Chang YF; Wu X
    Infect Dis Poverty; 2020 Jul; 9(1):88. PubMed ID: 32741372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: Implications for disease control and prevention.
    Guo E; Guo H
    PLoS One; 2020; 15(12):e0239566. PubMed ID: 33301503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection.
    Augusto DG; Hollenbach JA
    Curr Opin Immunol; 2022 Jun; 76():102178. PubMed ID: 35462277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection.
    Mahapatra SR; Sahoo S; Dehury B; Raina V; Patro S; Misra N; Suar M
    Expert Rev Vaccines; 2020 Sep; 19(9):871-885. PubMed ID: 32869699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis.
    Tomita Y; Sato R; Ikeda T; Sakagami T
    Vaccine; 2020 Sep; 38(41):6352-6356. PubMed ID: 32863070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions.
    Liu G; Carter B; Bricken T; Jain S; Viard M; Carrington M; Gifford DK
    Cell Syst; 2020 Aug; 11(2):131-144.e6. PubMed ID: 32721383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.